Using Real World Evidence to Describe Pulmonary Arterial Hypertension Treatment Patterns, Healthcare Resource Utilization, and Costs Associated with PDE-5 Inhibitor Monotherapy
**Background:** Pulmonary arterial hypertension (PAH) is described by proliferation of small pulmonary arteries leading to increased pulmonary vascular resistance, right ventricular failure, and death. Research confirms long-term improvement in composite morbidity and mortality endpoints on some end...
Saved in:
Main Authors: | George Ruiz, Jason Yeaw, Cassandra A. Lickert, Ajita P. De, Rolin L. Wade, Janis Pruett, William Drake |
---|---|
Format: | Article |
Language: | English |
Published: |
Columbia Data Analytics, LLC
2018-01-01
|
Series: | Journal of Health Economics and Outcomes Research |
Online Access: | https://doi.org/10.36469/9812 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of Oxycodone HCl Extended-release Formulary Restrictions on Extended-release Opioid Market Share, Healthcare Resource Utilization and Costs in Commercial and Medicare Plans
by: Rolin L. Wade, et al.
Published: (2017-07-01) -
Modulation of oxazolone-induced hypersensitivity in mice by selective PDE inhibitors
by: I. Moodley, et al.
Published: (1995-01-01) -
Penile Rehabilitation Therapy with PDE-V Inhibitors Following Radical Prostatectomy: Proceed with Caution
by: M. Eric Brewer, et al.
Published: (2009-01-01) -
Future perspectives for PDE5 inhibitors bridging the gap between cardiovascular health and psychological status
by: Andrea Sansone, et al.
Published: (2025-01-01) -
Addition of Sildenafil in Patients with Pulmonary Arterial Hypertension with Inadequate Response to Bosentan Monotherapy
by: Nancy R Porhownik, et al.
Published: (2008-01-01)